<DOC>
	<DOCNO>NCT03102320</DOCNO>
	<brief_summary>The key purpose main part study ass efficacy safety anetumab ravtansine monotherapy combination therapy mesothelin express advance solid tumor . The main purpose safety lead-in ( dose-finding ) part study determine safety tolerability anetumab ravtansine combination cisplatin combination gemcitabine , determine MTD anetumab ravtansine combination cisplatin mesothelin express advanced cholangiocarcinoma combination gemcitabine mesothelin express advanced adenocarcinoma pancreas . Patients receive anetumab ravtansine every three week monotherapy indication . In cholangiocarcinoma adenocarinoma pancreas , 3-weekly anetumab ravtansine administer combination cisplatin gemcitabine respectively ( administer 2 week / 1 week schedule ) . Treatment continue disease progression another criterion withdrawal meet . .Efficacy measure evaluate tumor 's objective response rate . Radiological tumor assessment perform defined time point patient 's disease progress . Blood sample collect safety , pharmacokinetic biomarker analysis . Archival fresh biopsy tissue may also collect review biomarkers .</brief_summary>
	<brief_title>Phase 1b Multi-indication Study Anetumab Ravtansine Mesothelin Expressing Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Maytansine</mesh_term>
	<mesh_term>Immunoconjugates</mesh_term>
	<criteria>Availability tumor tissue mesothelin expression test Histologicallyconfirmed , mesothelinexpressing metastatic advanced nonmetastatic disease ( tumour type specific inclusion criterion ) At least one measurable lesion accord either Response Evaluation Criteria Solid Tumors ( RECIST ) 1.1 International Thymic Malignancy Interest Group ( ITMIG ) modify RECIST 1.1 applicable Adequate bone marrow , liver , renal coagulation function Left ventricular ejection fraction ( LVEF ) â‰¥ 50 % low limit normal ( LLN ) accord local institutional range Eastern Cooperative Oncology Group ( ECOG ) 0 1 More one prior antitubulin/microtubule agent Corneal epitheliopathy eye disorder may predispose patient condition Symptomatic Central nervous system ( CNS ) metastases and/or carcinomatous meningitis Contraindication CT MRI contrast agent Active hepatitis B C infection Pregnant breastfeeding patient Tumor type specific exclusion criterion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>cholangiocarcinoma</keyword>
	<keyword>pancreatic cancer</keyword>
	<keyword>triple-negative breast cancer</keyword>
	<keyword>non-small cell lung cancer</keyword>
	<keyword>thymic carcinoma</keyword>
	<keyword>gastric include gastroesophageal junction cancer</keyword>
</DOC>